Galmed Pharmaceuticals (GLMD) Given a $14.00 Price Target by Maxim Group Analysts

Maxim Group set a $14.00 price objective on Galmed Pharmaceuticals (NASDAQ:GLMD) in a research report sent to investors on Wednesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages also recently commented on GLMD. Seaport Global Securities reaffirmed a buy rating and set a $19.00 target price on shares of Galmed Pharmaceuticals in a report on Friday, October 6th. Zacks Investment Research downgraded shares of Galmed Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, October 11th. HC Wainwright reiterated a buy rating and issued a $18.00 price objective on shares of Galmed Pharmaceuticals in a research note on Friday, October 27th. ValuEngine cut shares of Galmed Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, December 1st. Finally, Roth Capital assumed coverage on shares of Galmed Pharmaceuticals in a research note on Wednesday, November 15th. They issued a buy rating and a $32.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $18.30.

Shares of Galmed Pharmaceuticals (NASDAQ GLMD) opened at $8.09 on Wednesday. Galmed Pharmaceuticals has a twelve month low of $3.04 and a twelve month high of $9.59.

Institutional investors have recently modified their holdings of the business. GRT Capital Partners L.L.C. acquired a new position in shares of Galmed Pharmaceuticals in the 2nd quarter valued at approximately $114,000. KCG Holdings Inc. acquired a new position in Galmed Pharmaceuticals during the 1st quarter worth approximately $100,000. Finally, 683 Capital Management LLC increased its position in Galmed Pharmaceuticals by 9.9% during the 3rd quarter. 683 Capital Management LLC now owns 549,295 shares of the biopharmaceutical company’s stock worth $5,021,000 after purchasing an additional 49,295 shares in the last quarter. Institutional investors and hedge funds own 9.85% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Galmed Pharmaceuticals (GLMD) Given a $14.00 Price Target by Maxim Group Analysts” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://ledgergazette.com/2017/12/10/galmed-pharmaceuticals-glmd-given-a-14-00-price-target-by-maxim-group-analysts.html.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Receive News & Ratings for Galmed Pharmaceuticals Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply